| appearance as argument number 1 |
|
| (documentation Sarilumab EnglishLanguage "Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.[from Wikipedia]") | Medicine.kif 5262-5267 | |
| (subclass Sarilumab MonoclonalAntibody) | Medicine.kif 5260-5260 | Sarilumab is a subclass of monoclonal antibody |
| appearance as argument number 2 |
|
|
| (diseaseMedicine RheumatoidArthritis Sarilumab Injecting) | Medicine.kif 5269-5269 | Rheumatoid arthritis is disease treatment sarilumab for injecting |
| (subclass Kevzara Sarilumab) | Medicine.kif 5271-5271 | Kevzara is a subclass of sarilumab |
| (termFormat EnglishLanguage Sarilumab "sarilumab") | Medicine.kif 5268-5268 | Kevzara is a subclass of sarilumab |
|
Show full definition with tree view
Show simplified definition (without tree view)
Show simplified definition (with tree view)
|
|
Sigma web home Suggested Upper Merged Ontology (SUMO) web home
Sigma version 3.0 is open source software produced by Articulate Software and its partners